348 related articles for article (PubMed ID: 18006806)
1. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
[TBL] [Abstract][Full Text] [Related]
2. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective.
Rajasekhar VK; Begemann M
Stem Cells; 2007 Oct; 25(10):2498-510. PubMed ID: 17600113
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation.
van der Vlag J; Otte AP
Nat Genet; 1999 Dec; 23(4):474-8. PubMed ID: 10581039
[TBL] [Abstract][Full Text] [Related]
4. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation.
Montgomery ND; Yee D; Chen A; Kalantry S; Chamberlain SJ; Otte AP; Magnuson T
Curr Biol; 2005 May; 15(10):942-7. PubMed ID: 15916951
[TBL] [Abstract][Full Text] [Related]
5. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic mechanisms in the biology of prostate cancer.
Schulz WA; Hoffmann MJ
Semin Cancer Biol; 2009 Jun; 19(3):172-80. PubMed ID: 19429481
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of malignant renal stem cells is associated with epigenetic changes in normal renal progenitor genes.
Metsuyanim S; Pode-Shakked N; Schmidt-Ott KM; Keshet G; Rechavi G; Blumental D; Dekel B
Stem Cells; 2008 Jul; 26(7):1808-17. PubMed ID: 18467665
[TBL] [Abstract][Full Text] [Related]
8. [Epigenetic analyses of brain tumor stem cells].
Natsume A; Kondo Y; Wakabayashi T
Brain Nerve; 2009 Jul; 61(7):791-8. PubMed ID: 19618856
[TBL] [Abstract][Full Text] [Related]
9. DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines.
Reyes I; Tiwari R; Geliebter J; Reyes N
Biomedica; 2007 Jun; 27(2):190-203. PubMed ID: 17713630
[TBL] [Abstract][Full Text] [Related]
10. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.
Lapointe J; Malhotra S; Higgins JP; Bair E; Thompson M; Salari K; Giacomini CP; Ferrari M; Montgomery K; Tibshirani R; van de Rijn M; Brooks JD; Pollack JR
Am J Surg Pathol; 2008 Feb; 32(2):205-9. PubMed ID: 18223322
[TBL] [Abstract][Full Text] [Related]
11. Programming of gene expression by Polycomb group proteins.
Köhler C; Villar CB
Trends Cell Biol; 2008 May; 18(5):236-43. PubMed ID: 18375123
[TBL] [Abstract][Full Text] [Related]
12. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer.
Halvorsen OJ; Rostad K; Øyan AM; Puntervoll H; Bø TH; Stordrange L; Olsen S; Haukaas SA; Hood L; Jonassen I; Kalland KH; Akslen LA
Clin Cancer Res; 2007 Feb; 13(3):892-7. PubMed ID: 17289882
[TBL] [Abstract][Full Text] [Related]
14. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
16. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.
Setlur SR; Royce TE; Sboner A; Mosquera JM; Demichelis F; Hofer MD; Mertz KD; Gerstein M; Rubin MA
Cancer Res; 2007 Nov; 67(21):10296-303. PubMed ID: 17974971
[TBL] [Abstract][Full Text] [Related]
17. Biochemical mechanisms of gene regulation by polycomb group protein complexes.
Müller J; Verrijzer P
Curr Opin Genet Dev; 2009 Apr; 19(2):150-8. PubMed ID: 19345089
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
19. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition.
Pampalakis G; Prosnikli E; Agalioti T; Vlahou A; Zoumpourlis V; Sotiropoulou G
Cancer Res; 2009 May; 69(9):3779-87. PubMed ID: 19383923
[TBL] [Abstract][Full Text] [Related]
20. Gene silencing by the Polycomb group proteins and associations with cancer.
Lin YW; Chen HM; Fang JY
Cancer Invest; 2011 Mar; 29(3):187-95. PubMed ID: 21294604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]